for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Baxter International Inc

BAX.N

Latest Trade

88.00USD

Change

0.54(+0.62%)

Volume

469,006

Today's Range

87.64

 - 

88.30

52 Week Range

61.06

 - 

89.93

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
87.46
Open
87.70
Volume
469,006
3M AVG Volume
46.57
Today's High
88.30
Today's Low
87.64
52 Week High
89.93
52 Week Low
61.06
Shares Out (MIL)
510.56
Market Cap (MIL)
44,653.21
Forward P/E
25.85
Dividend (Yield %)
1.01

Next Event

Q3 2019 Baxter International Inc Earnings Release

Latest Developments

More

Baxter Launches Prismax In Canada To Maximize Treatment In ICU

Baxter Reports Second Quarter GAAP Earnings Per Share Of $0.66

Baxter Announces U.S. FDA Approval Of Myxredlin, Ready-To-Use Insulin For IV Infusion

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Baxter International Inc

Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.

Industry

Medical Equipment & Supplies

Contact Info

1 Baxter Pkwy

+1.847.9482000

https://www.baxter.com/

Executive Leadership

Jose E. Almeida

Chairman of the Board, President, Chief Executive Officer

James K. Saccaro

Chief Financial Officer, Executive Vice President

Brian Stevens

Senior Vice President, Chief Accounting Officer, Controller

Sean B. W. Martin

Senior Vice President, General Counsel

Jeanne K. Mason

Senior Vice President - Human Resources

Key Stats

2.12 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

10.2K

2017

10.6K

2018

11.1K

2019(E)

11.3K
EPS (USD)

2016

1.960

2017

2.480

2018

3.050

2019(E)

3.383
Price To Earnings (TTM)
33.47
Price To Sales (TTM)
4.03
Price To Book (MRQ)
5.71
Price To Cash Flow (TTM)
20.48
Total Debt To Equity (MRQ)
66.07
LT Debt To Equity (MRQ)
66.01
Return on Investment (TTM)
9.62
Return on Equity (TTM)
8.14

Latest News

U.S. closes IV solution shortage antitrust probe, Baxter says

Baxter International Inc said the U.S. Justice Department has closed an antitrust probe examining possible communication among producers of intravenous saline solutions during supply shortages that created higher prices.

UPDATE 1-Smiths Group, ICU Medical close to abandoning healthcare merger -Sky News

British engineering firm Smiths Group Plc is close to abandoning talks with U.S.-based ICU Medical Inc over a 7 billion pound ($9 billion) merger of their healthcare divisions, Sky News reported on Monday.

BRIEF-Baxter Declares Dividend And Announces Quarterly Dividend Increase

* BAXTER DECLARES DIVIDEND AND ANNOUNCES QUARTERLY DIVIDEND INCREASE

BRIEF-Baxter International Posts Q1 GAAP Earnings Per Share $0.71 From Continuing Operations

* BAXTER REPORTS FIRST-QUARTER 2018 RESULTS AND INCREASES FINANCIAL OUTLOOK FOR FULL-YEAR 2018

BRIEF-Ameren CEO Warner Baxter's 2017 Total Compensation Was $8.1 Mln

* AMEREN CORP CEO WARNER L. BAXTER'S 2017 TOTAL COMPENSATION WAS $8.1 MILLION VERSUS $6.6 MILLION IN 2016 – SEC FILING Source text - http://bit.ly/2FOolXi Further company coverage:

BRIEF-Baxter Announces Dividend, Additional Share Repurchase

* BAXTER DECLARES QUARTERLY DIVIDEND AND ANNOUNCES EXPANDED SHARE REPURCHASE AUTHORIZATION

Baxter forecasts upbeat 2018; expects more buybacks, deals

Baxter International Inc <BAX.N> on Thursday forecast 2018 earnings largely ahead of analysts' estimates and said it would continue to be active on the acquisition front and repurchase more shares through the year.

BRIEF-Baxter Reports Q4 Adjusted EPS Of $0.64​

* Q4 EARNINGS PER SHARE VIEW $0.59 -- THOMSON REUTERS I/B/E/S

Baxter International reports quarterly loss due to tax charge

Baxter International Inc reported quarterly loss versus year-ago profit as the hospital products maker took a charge of $354 million due to changes in the U.S. tax law.

Baxter to import IV saline bags from Mexico to ease U.S. shortage

(This version of the Jan. 24 story corrects the number of Baxter plants in Puerto Rico making small IV bags to two from three in paragraph five)

BRIEF-Baxter Announces U.S. FDA Approval Of Ready-To-Use Bivalirudin

* BAXTER ANNOUNCES U.S. FDA APPROVAL OF READY-TO-USE CARDIOVASCULAR MEDICATION BIVALIRUDIN

BRIEF-Baxter International-On Jan 1,Administrative Committee Of Compensation Committee Of Board Approved Amendment To Reorganize Co's, Units Pension Plan

* BAXTER INTERNATIONAL-ON JAN 1,ADMINISTRATIVE COMMITTEE OF COMPENSATION COMMITTEE OF BOARD APPROVED AMENDMENT TO REORGANIZE CO'S,UNITS PENSION PLAN

BRIEF-Baxter To Acquire Recothrom, Preveleak For Upfront Payment Of About $153 Mln

* BAXTER ANNOUNCES AGREEMENT TO BROADEN PORTFOLIO OF INNOVATIVE SURGICAL PRODUCTS

Baxter expects $70 million hit to fourth-quarter sales from Hurricane Maria

U.S. hospital products maker Baxter International Inc on Wednesday forecast a nearly $70 million hit to its fourth-quarter revenue, due to manufacturing disruptions arising from Hurricane Maria.

Baxter expects $70 mln hit to 4th-qtr sales from Hurricane Maria

Hospital products maker Baxter International Inc on Wednesday forecast a nearly $70 million hit to its fourth-quarter revenue due to manufacturing disruptions arising from Hurricane Maria.

BRIEF-Baxter provides update on Puerto Rico recovery status post Hurricane Maria

* Baxter provides update on Puerto Rico recovery status post Hurricane Maria

BRIEF-Baxter International Inc - ‍launches DeviceVue Advanced Asset Tracking System for Sigma Spectrum Infusion System​

* Baxter International Inc - launches DeviceVue Advanced Asset Tracking System for Sigma Spectrum Infusion System Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Baxter International ‍announces commercial launch of new indication for oXiris set​

* Baxter launches first 3-in-1 set for use in continuous renal replacement therapy and sepsis management protocols

BRIEF-Baxter and MATTER Healthcare on patient-driven innovation

* Baxter and MATTER Healthcare Incubator Partner on patient-driven innovation

Big-name U.S. hedge funds shed healthcare stocks during the rally in second-quarter

Several big-name hedge fund investors trimmed their stakes in healthcare companies in the second quarter as the sector led the broad U.S. stock market higher, rallying amid a Republican effort to repeal and replace President Obama's signature healthcare law.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up